{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:21:55Z","timestamp":1793992915943,"version":"4.8.0"},"reference-count":202,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003347","name":"Fudan University","doi-asserted-by":"publisher","award":["2023ZSCX06"],"award-info":[{"award-number":["2023ZSCX06"]}],"id":[{"id":"10.13039\/501100003347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303886"],"award-info":[{"award-number":["82303886"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010108","name":"Zhongshan Hospital","doi-asserted-by":"publisher","award":["2024ZSFZ05"],"award-info":[{"award-number":["2024ZSFZ05"]}],"id":[{"id":"10.13039\/501100010108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2411404"],"award-info":[{"award-number":["2023YFC2411404"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFC2417505"],"award-info":[{"award-number":["2024YFC2417505"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biomaterials.2026.124208","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T23:10:39Z","timestamp":1775689839000},"page":"124208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Interventional therapy for hepatocellular carcinoma in the immunotherapy era: From mechanism exploration to materials innovation"],"prefix":"10.1016","volume":"333","author":[{"given":"Bufu","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weishi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juncheng","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqiao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-3036","authenticated-orcid":false,"given":"Xudong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biomaterials.2026.124208_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41392-024-02075-w","article-title":"Hepatocellular carcinoma: signaling pathways and therapeutic advances","volume":"10","author":"Zheng","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124208_bib3","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3748\/wjg.v29.i8.1243","article-title":"Predictors of early and late hepatocellular carcinoma recurrence","volume":"29","author":"Nevola","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biomaterials.2026.124208_bib4","doi-asserted-by":"crossref","first-page":"13805","DOI":"10.2147\/IJN.S490661","article-title":"Nanotechnology for the diagnosis and treatment of liver cancer","volume":"19","author":"Cai","year":"2024","journal-title":"Int. J. Nanomed."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124208_bib5","article-title":"The evolving role of immune checkpoint inhibitors in hepatocellular carcinoma treatment","volume":"9","author":"Leone","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124208_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124208_bib7","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1111\/liv.15052","article-title":"Paradigm shift in the treatment options of hepatocellular carcinoma","volume":"42","author":"Su","year":"2022","journal-title":"Liver Int."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124208_bib8","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.cgh.2023.01.039","article-title":"Breakthroughs in hepatocellular carcinoma therapies","volume":"21","author":"Singal","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"21","key":"10.1016\/j.biomaterials.2026.124208_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/ijms21218165","article-title":"Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma","volume":"21","author":"Chang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124208_bib10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12072-015-9700-7","article-title":"Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review","volume":"10","author":"Wang","year":"2016","journal-title":"Hepatol. Int."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124208_bib11","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1016\/j.acra.2024.04.045","article-title":"Transarterial chemoembolization (TACE) combined with Lenvatinib versus TACE alone in intermediate-stage hepatocellular carcinoma patients beyond up-to-seven criteria: a retrospective, propensity score-matched analysis","volume":"31","author":"Zhou","year":"2024","journal-title":"Acad. Radiol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124208_bib12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1148\/radiol.2018171541","article-title":"Advanced recurrent hepatocellular carcinoma: treatment with sorafenib alone or in combination with transarterial chemoembolization and radiofrequency ablation","volume":"287","author":"Peng","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.biomaterials.2026.124208_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/hep.32447","article-title":"Emerging immunotherapy for hepatocellular carcinoma: a guide for hepatologists","author":"Foerster","year":"2022","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmed.2026.100003","article-title":"The promise and potential of liver organoids: development, classification and application","volume":"1","author":"Wang","year":"2026","journal-title":"TransMed"},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124208_bib15","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124208_bib16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biomaterials.2026.124208_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fimmu.2024.1418965","article-title":"The current status and future of targeted-immune combination for hepatocellular carcinoma","volume":"15","author":"Hao","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-024-01549-2","article-title":"Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives","volume":"17","author":"Shen","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124208_bib19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124208_bib20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.21037\/jgo.2016.09.07","article-title":"Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy","volume":"8","author":"Kim","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"issue":"29","key":"10.1016\/j.biomaterials.2026.124208_bib21","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.3748\/wjg.v23.i29.5282","article-title":"From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world","volume":"23","author":"Dimitroulis","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"30","key":"10.1016\/j.biomaterials.2026.124208_bib22","first-page":"19","article-title":"Drug-eluting porous embolic microspheres for trans-arterial delivery of dual synergistic anticancer therapy for the treatment of liver cancer","volume":"12","author":"Amoyav","year":"2023","journal-title":"Adv. Healthcare Mater."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124208_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/wnan.1749","article-title":"Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma","volume":"14","author":"Jia","year":"2022","journal-title":"Wiley Interdiscip. Rev., Nanomed. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124208_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1053\/j.ro.2016.02.005","article-title":"Transarterial therapies for hepatocellular carcinoma","volume":"51","author":"Makramalla","year":"2016","journal-title":"Semin. Roentgenol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/hep.32779","article-title":"Risk stratification and early detection biomarkers for precision HCC screening","volume":"78","author":"Lee","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124208_bib26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/MCG.0000000000001668","article-title":"Utilization of hepatocellular carcinoma surveillance programs in patients with cirrhosis A systematic review and meta-analysis","volume":"57","author":"Ramai","year":"2023","journal-title":"J. Clin. Gastroenterol."},{"issue":"36","key":"10.1016\/j.biomaterials.2026.124208_bib27","doi-asserted-by":"crossref","first-page":"10327","DOI":"10.3748\/wjg.v21.i36.10327","article-title":"Transarterial chemoembolization in hepatocellular carcinoma treatment: barcelona clinic liver cancer staging system","volume":"21","author":"Han","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biomaterials.2026.124208_bib28","doi-asserted-by":"crossref","first-page":"ii24","DOI":"10.1093\/annonc\/mdt054","article-title":"Intermediate hepatocellular carcinoma: current treatments and future perspectives","volume":"24","author":"Dufour","year":"2013","journal-title":"Ann. Oncol."},{"issue":"9319","key":"10.1016\/j.biomaterials.2026.124208_bib29","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124208_bib30","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s12072-023-10502-3","article-title":"Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma","volume":"17","author":"Xin","year":"2023","journal-title":"Hepatol. Int."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124208_bib32","doi-asserted-by":"crossref","first-page":"374","DOI":"10.5582\/bst.2019.01153","article-title":"The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis","volume":"13","author":"Han","year":"2019","journal-title":"BioSci Trends"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/liv.12649","article-title":"BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group","volume":"35","author":"Farinati","year":"2015","journal-title":"Liver Int."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124208_bib34","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/gutjnl-2020-320692","article-title":"Changing TACTICS in intermediate HCC: TACE plus sorafenib","volume":"69","author":"Radu","year":"2020","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124208_bib35","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124208_bib36","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s12072-021-10184-9","article-title":"Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study","volume":"15","author":"Fu","year":"2021","journal-title":"Hepatol. Int."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41392-024-01991-1","article-title":"Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124208_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/jamanetworkopen.2020.23942","article-title":"Association of addition of ablative therapy following transarterial chemoembolization with survival rates in patients with hepatocellular carcinoma","volume":"3","author":"English","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124208_bib40","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamaoncol.2024.1831","article-title":"Survival in patients with recurrent intermediate-stage hepatocellular Carcinoma Sorafenib plus TACE vs TACE alone randomized clinical trial","volume":"10","author":"Fan","year":"2024","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-023-01723-x","volume":"9","author":"Duan","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jitc-2024-010035","article-title":"Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria","volume":"13","author":"Li","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124208_bib44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/hep.31424","article-title":"Local and regional therapies for hepatocellular carcinoma","volume":"73","author":"Kloeckner","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.biomaterials.2026.124208_bib45","first-page":"9","article-title":"PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma","author":"Fessas","year":"2023","journal-title":"Future Oncol."},{"issue":"10474","key":"10.1016\/j.biomaterials.2026.124208_bib46","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib47","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41392-024-01991-1","article-title":"Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124208_bib48","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/liv.15831","article-title":"Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: a phase II study","volume":"44","author":"Cai","year":"2024","journal-title":"Liver Int."},{"issue":"10474","key":"10.1016\/j.biomaterials.2026.124208_bib49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124208_bib50","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2217\/fon-2021-1261","article-title":"Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol","volume":"18","author":"Ben","year":"2022","journal-title":"Future Oncol."},{"issue":"35","key":"10.1016\/j.biomaterials.2026.124208_bib51","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1200\/JCO.21.01993","article-title":"Transarterial radioembolization in patients with unresectable colorectal cancer liver metastases","volume":"39","author":"Lentz","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124208_bib52","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jhep.2022.08.003","article-title":"Interventional radiology meets immuno-oncology for hepatocellular carcinoma","volume":"80","author":"Salem","year":"2024","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124208_bib53","first-page":"17","article-title":"What to do about hepatocellular carcinoma: recommendations for health authorities from the International Liver Cancer Association","volume":"4","author":"Allaire","year":"2022","journal-title":"JHEP Rep."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124208_bib54","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s12072-016-9722-9","article-title":"Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality","volume":"10","author":"Kim","year":"2016","journal-title":"Hepatol. Int."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124208_bib55","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","article-title":"90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial","volume":"303","author":"Dhondt","year":"2022","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124208_bib56","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/liv.12637","article-title":"In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?","volume":"35","author":"El","year":"2015","journal-title":"Liver Int."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124208_bib57","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124208_bib58","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124208_bib59","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124208_bib60","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2019.01.027","article-title":"Combined locoregional-immunotherapy for liver cancer","volume":"70","author":"Greten","year":"2019","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124208_bib61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jitc-2021-003311","article-title":"Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy","volume":"9","author":"Pinato","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124208_bib62","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2019.09.023","article-title":"Role of locoregional therapies in the wake of systemic therapy","volume":"72","author":"Palmer","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biomaterials.2026.124208_bib63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/JHC.S187121","article-title":"The immune modulation effect of locoregional therapies and its potential synergy with immunotherapy in hepatocellular carcinoma","volume":"7","author":"Singh","year":"2020","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124208_bib64","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124208_bib65","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/s41418-017-0044-9","article-title":"eIF2\u03b1 phosphorylation is pathognomonic for immunogenic cell death","volume":"25","author":"Bezu","year":"2018","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124208_bib67","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","article-title":"Targeting immunogenic cell stress and death for cancer therapy","volume":"23","author":"Galluzzi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124208_bib68","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s13277-012-0504-2","article-title":"Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy","volume":"33","author":"Kohles","year":"2012","journal-title":"Tumor Biol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124208_bib69","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","article-title":"Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma","volume":"68","author":"Chew","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib70","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","article-title":"TREM2+macrophages suppress CD8+T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma","volume":"79","author":"Tan","year":"2023","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124208_bib71","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s12013-015-0699-0","article-title":"Effect of transcatheter arterial chemoembolization combined with argon-helium cryosurgery system on the changes of NK cells and T cell subsets in peripheral blood of hepatocellular carcinoma patients","volume":"73","author":"Huang","year":"2015","journal-title":"Cell Biochem. Biophys."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124208_bib72","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.3892\/mmr.2015.4171","article-title":"Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma","volume":"12","author":"Liao","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124208_bib73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1371\/journal.pone.0060444","article-title":"Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study","volume":"8","author":"Liao","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124208_bib74","doi-asserted-by":"crossref","first-page":"E1489","DOI":"10.1634\/theoncologist.2018-0669","article-title":"Postintervention Interleukin-6 (IL-6) level, rather than the pretreatment or dynamic changes of IL-6, as an early practical marker of tumor response in hepatocellular carcinoma treated with transarterial chemoembolization","volume":"24","author":"Wu","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10238-020-00667-8","article-title":"Prognostic value of serum HIF-1\u03b1 change following transarterial chemoembolization in hepatocellular carcinoma","volume":"21","author":"Lin","year":"2021","journal-title":"Clin. Exp. Med."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124208_bib76","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/02841850801958890","article-title":"Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization","volume":"49","author":"Wang","year":"2008","journal-title":"Acta Radiol."},{"key":"10.1016\/j.biomaterials.2026.124208_bib77","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jconrel.2024.06.026","article-title":"Sustained release hypoxia-activated prodrug-loaded BSA nanoparticles enhance transarterial chemoembolization against hepatocellular carcinoma","volume":"372","author":"Hao","year":"2024","journal-title":"J. Contr. Release"},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124208_bib78","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00432-014-1713-4","article-title":"Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1\u03b1 pathway in patients with hepatocellular carcinoma","volume":"140","author":"Xu","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124208_bib79","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00270-019-02343-1","article-title":"Hepatic arterial bland embolization increases Th17 cell infiltration in a syngeneic rat model of hepatocellular carcinoma","volume":"43","author":"Avritscher","year":"2020","journal-title":"Cardiovasc. Interv. Radiol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib80","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1148\/radiol.211028","article-title":"Transarterial embolization modulates the immune response within target and nontarget hepatocellular carcinomas in a rat model","volume":"303","author":"Tischfield","year":"2022","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124208_bib81","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3350\/cmh.2021.0308","article-title":"Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma","volume":"28","author":"Sung","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib82","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124208_bib83","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/hep.32447","article-title":"Emerging immunotherapy for HCC: a guide for hepatologists","volume":"75","author":"Foerster","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.biomaterials.2026.124208_bib84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.smim.2023.101739","article-title":"TREM2: a new player in the tumor microenvironment","volume":"67","author":"Molgora","year":"2023","journal-title":"Semin. Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib85","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13046-025-03287-w","article-title":"TREM2 promotes the formation of a tumor-supportive microenvironment in hepatocellular carcinoma","volume":"44","author":"Guo","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124208_bib86","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","article-title":"CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential","volume":"55","author":"Koh","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124208_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.390","article-title":"The role of CD4+ T cells in tumor and chronic viral immune responses","volume":"4","author":"Xie","year":"2023","journal-title":"MedComm"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124208_bib88","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.it.2024.02.005","article-title":"Regulation and impact of tumor-specific CD4+T cells in cancer and immunotherapy","volume":"45","author":"Guo","year":"2024","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib89","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124208_bib90","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nri.2017.118","article-title":"TH2 cell development and function","volume":"18","author":"Walker","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124208_bib91","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/intimm\/dxw025","article-title":"Roles of regulatory T cells in cancer immunity","volume":"28","author":"Takeuchi","year":"2016","journal-title":"Int. Immunol."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124208_bib92","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","article-title":"The roles of CD8+ T cell subsets in antitumor immunity","volume":"30","author":"St Paul","year":"2020","journal-title":"Trends Cell Biol."},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124208_bib93","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124208_bib94","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2022.02.032","article-title":"T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma","volume":"77","author":"Barsch","year":"2022","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124208_bib95","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12072-020-10014-4","article-title":"Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma","volume":"14","author":"Park","year":"2020","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.biomaterials.2026.124208_bib96","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.intimp.2024.111601","article-title":"Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma","volume":"129","author":"Song","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"19","key":"10.1016\/j.biomaterials.2026.124208_bib97","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.3748\/wjg.v10.i19.2878","article-title":"Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level","volume":"10","author":"Li","year":"2004","journal-title":"World J. Gastroenterol."},{"issue":"7655","key":"10.1016\/j.biomaterials.2026.124208_bib98","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124208_bib99","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s12072-023-10519-8","article-title":"Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study","volume":"17","author":"Duan","year":"2023","journal-title":"Hepatol. Int."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-01235-0","article-title":"Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124208_bib101","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1007\/s00330-023-09754-2","article-title":"Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study","volume":"33","author":"Jin","year":"2023","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.biomaterials.2026.124208_bib102","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fimmu.2023.1205636","article-title":"Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study","volume":"14","author":"Jiang","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib103","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12935-022-02771-z","article-title":"Targeted blocking of CCR2 and CXCR2 improves the efficacy of transarterial chemoembolization of hepatocarcinoma","volume":"22","author":"Tian","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124208_bib104","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004205","article-title":"Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study","volume":"10","author":"Marinelli","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010035","article-title":"Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria","volume":"13","author":"Li","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124208_bib106","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000054","article-title":"Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: a phase II trial","volume":"7","author":"Guo","year":"2023","journal-title":"Hepatol. Commun."},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124208_bib107","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/fon-2022-0916","article-title":"PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma","volume":"19","author":"Fessas","year":"2023","journal-title":"Future Oncol."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124208_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107106","article-title":"Neoadjuvant drug-eluting bead transarterial chemoembolization and tislelizumab therapy for resectable or borderline resectable hepatocellular carcinoma: a propensity score matching analysis","volume":"49","author":"Zhao","year":"2023","journal-title":"Eur. J. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124208_bib109","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/15384047.2018.1433501","article-title":"A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE","volume":"19","author":"Zhang","year":"2018","journal-title":"Cancer Biol. Ther."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124208_bib110","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.annonc.2024.03.005","article-title":"Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040","volume":"35","author":"Melero","year":"2024","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124208_bib111","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with Anti-CTLA-4 and Anti-PD-1 leads to distinct immunologic changes in vivo","volume":"194","author":"Das","year":"2015","journal-title":"J. Immunol."},{"issue":"20","key":"10.1016\/j.biomaterials.2026.124208_bib112","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124208_bib113","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/biomedicines11071878","article-title":"LAG-3 inhibitors: novel immune checkpoint inhibitors changing the landscape of immunotherapy","volume":"11","author":"Ibrahim","year":"2023","journal-title":"Biomedicines"},{"issue":"16","key":"10.1016\/j.biomaterials.2026.124208_bib114","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8+T cells to drive T cell exhaustion and hinder autocrine IFN-y-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41392-021-00784-0","article-title":"GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages","volume":"6","author":"Chen","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"10","key":"10.1016\/j.biomaterials.2026.124208_bib116","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.celrep.2023.113224","article-title":"Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity","volume":"42","author":"Zhong","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.biomaterials.2026.124208_bib117","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.redox.2022.102463","article-title":"Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing","volume":"56","author":"Hao","year":"2022","journal-title":"Redox Biol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib118","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/gutjnl-2015-310514","article-title":"Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma","volume":"66","author":"Li","year":"2017","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib119","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jitc-2019-000317","article-title":"Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib","volume":"8","author":"Yang","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.biomaterials.2026.124208_bib120","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1136\/gutjnl-2022-327924","article-title":"MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression","volume":"72","author":"Fu","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.biomaterials.2026.124208_bib121","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.biomaterials.2022.121512","article-title":"HIF-2a-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma","volume":"284","author":"Chen","year":"2022","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124208_bib122","first-page":"4460","article-title":"Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages","volume":"40","author":"Fidler","year":"1980","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.biomaterials.2026.124208_bib123","doi-asserted-by":"crossref","first-page":"10583","DOI":"10.1016\/S0021-9258(19)70345-7","article-title":"Solubilization and reconstitution of the lactose transport system from Escherichia coli","volume":"255","author":"Newman","year":"1980","journal-title":"J. Biol. Chem."},{"issue":"8559","key":"10.1016\/j.biomaterials.2026.124208_bib124","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0140-6736(87)93011-X","article-title":"Reduction in toxicity of doxorubicin by liposomal entrapment","volume":"2","author":"Sells","year":"1987","journal-title":"Lancet (London, England)"},{"issue":"17","key":"10.1016\/j.biomaterials.2026.124208_bib125","first-page":"4817","article-title":"Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro","volume":"52","author":"Ahmad","year":"1992","journal-title":"Cancer Res."},{"issue":"5791","key":"10.1016\/j.biomaterials.2026.124208_bib126","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/288602a0","article-title":"Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A","volume":"288","author":"Leserman","year":"1980","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.biomaterials.2026.124208_bib127","first-page":"3320","article-title":"In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma","volume":"58","author":"Lopes de Menezes","year":"1998","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124208_bib128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae - the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2026.124208_bib129","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.addr.2017.02.003","article-title":"The battle of \"nano\" paclitaxel","volume":"122","author":"Sofias","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib130","first-page":"25","article-title":"Pulmonary delivery of nonviral nucleic acid-based vaccines with spotlight on gold nanoparticles","volume":"17","author":"Cirne","year":"2025","journal-title":"Wiley Interdiscip. Rev., Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.biomaterials.2026.124208_bib131","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/IJN.S499938","article-title":"A ferritin-based Eg95 nanoparticle vaccine adjuvanted with pCpG eliciting robust immune responses against cystic echinococcosis in mice model","volume":"20","author":"Gao","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biomaterials.2026.124208_bib132","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.aca.2024.343555","article-title":"A label-free electrochemical biosensor based on graphene quantum dots-nanoporous gold nanocomposite for highly sensitive detection of glioma cell","volume":"1337","author":"Wang","year":"2025","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.biomaterials.2026.124208_bib133","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.aca.2024.343545","article-title":"Visible light-responsive enrofloxacin PEC aptasensor based on CN QDs sensitized Bi4O5Br2 nanosheets","volume":"1337","author":"Ding","year":"2025","journal-title":"Anal. Chim. Acta"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib134","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-024-01628-4","article-title":"Personalized nanovaccines for treating solid cancer metastases","volume":"17","author":"Feng","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124208_bib135","first-page":"12","article-title":"Multifunctional biomimetic nanovaccines based on photothermal and weak-immunostimulatory nanoparticulate cores for the immunotherapy of solid tumors","volume":"34","author":"Li","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2026.124208_bib136","first-page":"14","article-title":"Macrophage membrane-based biomimetic nanocarrier system for enhanced immune activation and combination therapy in liver cancer","author":"Ni","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.biomaterials.2026.124208_bib137","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.actbio.2021.05.031","article-title":"Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer","volume":"130","author":"Liu","year":"2021","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib138","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41598-024-75332-1","article-title":"Polymeric nanoparticles loaded with vincristine and carbon dots for hepatocellular carcinoma therapy and imaging","volume":"14","author":"Fawaz","year":"2024","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124208_bib141","article-title":"Arginine-Loaded nano-calcium-phosphate-stabilized lipiodol pickering emulsions potentiates transarterial embolization-immunotherapy","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib142","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12951-022-01385-x","article-title":"Homogenous multifunctional microspheres induce ferroptosis to promote the Anti-hepatocarcinoma effect of chemoembolization","volume":"20","author":"Chen","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biomaterials.2026.124208_bib143","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jcis.2021.02.022","article-title":"Periodic mesoporous organosilica-coated magnetite nanoparticles combined with lipiodol for transcatheter arterial chemoembolization to inhibit the progression of liver cancer","volume":"591","author":"Liu","year":"2021","journal-title":"J. Colloid Interface Sci."},{"issue":"19","key":"10.1016\/j.biomaterials.2026.124208_bib144","doi-asserted-by":"crossref","first-page":"8817","DOI":"10.1039\/D1NR01268A","article-title":"Magnetic liquid metal loaded nano-in-micro spheres as fully flexible theranostic agents for SMART embolization","volume":"13","author":"Wang","year":"2021","journal-title":"Nanoscale"},{"issue":"37","key":"10.1016\/j.biomaterials.2026.124208_bib145","doi-asserted-by":"crossref","first-page":"8684","DOI":"10.1039\/D0TB01295E","article-title":"Nanosized drug-eluting bead for transcatheter arterial chemoembolization (ND-TACE)","volume":"8","author":"Zhao","year":"2020","journal-title":"J. Mater. Chem. B"},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124208_bib146","doi-asserted-by":"crossref","first-page":"11431","DOI":"10.1021\/acsami.2c18267","article-title":"Autophagy-targeted calcium phosphate nanoparticles enable transarterial chemoembolization for enhanced cancer therapy","volume":"15","author":"Yuan","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"38","key":"10.1016\/j.biomaterials.2026.124208_bib147","doi-asserted-by":"crossref","first-page":"20002","DOI":"10.1039\/D0NR04592F","article-title":"A versatile UCST-type composite microsphere for image-guided chemoembolization and photothermal therapy against liver cancer","volume":"12","author":"Huang","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.biomaterials.2026.124208_bib148","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jconrel.2024.06.026","article-title":"Sustained release hypoxia-activated prodrug-loaded BSA nanoparticles enhance transarterial chemoembolization against hepatocellular carcinoma","volume":"372","author":"Hao","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2026.124208_bib149","article-title":"Emulsifying Lipiodol with pH-sensitive DOX@HmA nanoparticles for hepatocellular carcinoma TACE treatment eliminate metastasis","volume":"23","author":"Shi","year":"2023","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.biomaterials.2026.124208_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122480","article-title":"Hypoxia-activated cascade nanovaccine for synergistic chemoembolization-immune therapy of hepatocellular carcinoma","volume":"306","author":"Shi","year":"2024","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib151","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwad257","article-title":"Self-fueling ferroptosis-inducing microreactors based on pH-responsive Lipiodol Pickering emulsions enable transarterial ferro-embolization therapy","volume":"11","author":"Wang","year":"2024","journal-title":"Natl. Sci. Rev."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124208_bib152","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.7150\/thno.68456","article-title":"A super-stable homogeneous Lipiodol-hydrophilic chemodrug formulation for treatment of hepatocellular carcinoma","volume":"12","author":"He","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib139","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12951-023-01804-7","article-title":"Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer: state of the art","volume":"21","author":"Wu","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12951-020-0581-0","article-title":"Photosensitive and dual-targeted chromium nanoparticle delivering small interfering RNA YTHDF1 for molecular-targeted immunotherapy in liver cancer","volume":"22","author":"Chen","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124208_bib153","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/advs.202410484","article-title":"Arginine-loaded nano-calcium-phosphate-stabilized lipiodol pickering emulsions potentiates transarterial embolization-immunotherapy","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib154","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12951-024-02887-6","article-title":"Co-delivery of polyphyllin II and IR780 PLGA nanoparticles induced pyroptosis combined with photothermal to enhance hepatocellular carcinoma immunotherapy","volume":"22","author":"Huang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biomaterials.2026.124208_bib155","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.actbio.2022.09.054","article-title":"CT\/MR detectable magnetic microspheres for self-regulating temperature hyperthermia and transcatheter arterial chemoembolization","volume":"153","author":"Wei","year":"2022","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib156","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12951-023-01820-7","article-title":"Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma","volume":"21","author":"Yuan","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124208_bib157","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.taap.2005.01.008","article-title":"Respiratory toxicity of multi-wall carbon nanotubes","volume":"207","author":"Muller","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmed.2026.100002","article-title":"Nanocarrier-induced inflammation: mechanisms, immunometabolic impacts and strategies for safer design","volume":"1","author":"Sahu","year":"2026","journal-title":"TransMed"},{"issue":"21","key":"10.1016\/j.biomaterials.2026.124208_bib159","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218165","article-title":"Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma","volume":"21","author":"Chang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib160","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12951-024-02547-9","article-title":"Functional hydrogels for hepatocellular carcinoma: therapy, imaging, and in vitro model","volume":"22","author":"Xu","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biomaterials.2026.124208_bib161","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3389\/fchem.2019.00408","article-title":"Recent advances on polymeric beads or hydrogels as embolization agents for improved transcatheter arterial chemoembolization (TACE)","volume":"7","author":"Chen","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.biomaterials.2026.124208_bib162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2022.07.019","article-title":"Embolization therapy with microspheres for the treatment of liver cancer: State-of-the-art of clinical translation","volume":"149","author":"P\u00e9rez-L\u00f3pez","year":"2022","journal-title":"Acta Biomater."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124208_bib163","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1749","article-title":"Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma","volume":"14","author":"Jia","year":"2022","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.biomaterials.2026.124208_bib164","doi-asserted-by":"crossref","first-page":"9621","DOI":"10.2147\/IJN.S527518","article-title":"Application of nanotechnology in TACE treatment of liver cancer","volume":"20","author":"Yao","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biomaterials.2026.124208_bib165","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.actbio.2022.12.004","article-title":"Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma","volume":"157","author":"Zheng","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.biomaterials.2026.124208_bib166","article-title":"Celecoxib and cisplatin dual-loaded microspheres synergistically enhance transarterial chemoembolization effect of hepatocellular carcinoma","volume":"24","author":"Wu","year":"2024","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.biomaterials.2026.124208_bib167","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124208_bib168","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov."},{"issue":"27","key":"10.1016\/j.biomaterials.2026.124208_bib169","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adv0885","article-title":"Magnesium microspheres for enhanced transarterial chemoembolization therapy of hepatocellular carcinoma: from animal models to a pilot clinical study","volume":"11","author":"Gong","year":"2025","journal-title":"Sci. Adv."},{"issue":"50","key":"10.1016\/j.biomaterials.2026.124208_bib170","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202510798","article-title":"Hypoxia\u2010 and pH\u2010Responsive metal\u2010phenolic network\u2010engineered ferroptosis\u2010immuno microspheres for transarterial chemoembolization in hepatocellular carcinoma","volume":"35","author":"Li","year":"2025","journal-title":"Adv. Funct. Mater."},{"issue":"19","key":"10.1016\/j.biomaterials.2026.124208_bib171","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202100748","article-title":"CaCO(3) -Encapuslated microspheres for enhanced transhepatic arterial embolization treatment of hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2021","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.biomaterials.2026.124208_bib172","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.actbio.2025.04.042","article-title":"Immune-activated microspheres for enhanced chemoembolization of hepatocellular carcinoma by blocking the adenosine A2A receptor","volume":"199","author":"Chen","year":"2025","journal-title":"Acta Biomater."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124208_bib173","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1021\/acsami.5c24260","article-title":"PD-L1 blockade with biodegradable envafolimab-loaded microspheres synergizes with transarterial chemoembolization to overcome myeloid-derived suppressor cell-driven immune escape in hepatocellular carcinoma","volume":"18","author":"Liu","year":"2026","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"29","key":"10.1016\/j.biomaterials.2026.124208_bib174","doi-asserted-by":"crossref","first-page":"25536","DOI":"10.1021\/jacs.5c06039","article-title":"Engineered nano-micro pyroptosis generators: a magnetic-metallo-immunotherapeutic strategy to reinforce transarterial embolization","volume":"147","author":"Wang","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"39","key":"10.1016\/j.biomaterials.2026.124208_bib175","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202505770","article-title":"A gas nanobomb to promote drug penetration and amplify TACE therapy for orthotopic liver tumor","volume":"37","author":"Chen","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2026.124208_bib176","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.actbio.2024.07.022","article-title":"Temperature-sensitive nanogels combined with polyphosphate and cisplatin for the enhancement of tumor artery embolization by coagulation activation","volume":"185","author":"Shi","year":"2024","journal-title":"Acta Biomater."},{"issue":"43","key":"10.1016\/j.biomaterials.2026.124208_bib177","article-title":"Lactate-modulating nanoreactors facilitate self-amplifying pyroptosis and the cGAS-STING Cascade for potentiated catalytic-immunotherapy","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124208_bib178","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ar.20668","article-title":"Vascular changes in hepatocellular carcinoma","volume":"291","author":"Yang","year":"2008","journal-title":"Anat. Rec."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib179","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","author":"European Assoc Study","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biomaterials.2026.124208_bib180","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drup.2021.100790","article-title":"Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma?","volume":"59","author":"Icard","year":"2021","journal-title":"Drug Resist. Updates"},{"issue":"32","key":"10.1016\/j.biomaterials.2026.124208_bib181","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.3748\/wjg.v25.i32.4614","article-title":"Locoregional treatments for hepatocellular carcinoma: current evidence and future directions","volume":"25","author":"Inchingolo","year":"2019","journal-title":"World J. Gastroenterol."},{"issue":"23","key":"10.1016\/j.biomaterials.2026.124208_bib182","first-page":"21","article-title":"Limitations and possibilities of transarterial chemotherapeutic treatment of hepatocellular carcinoma","volume":"22","author":"Barbier","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib183","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12964-021-00796-x","article-title":"Drug delivery strategy in hepatocellular carcinoma therapy","volume":"20","author":"Yang","year":"2022","journal-title":"Cell Commun. Signal."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124208_bib184","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/cancers12092637","article-title":"Immunogenic cell death and elimination of immunosuppressive cells: a double-edged sword of chemotherapy","volume":"12","author":"Fumet","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124208_bib185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124208_bib186","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.ymthe.2023.01.017","article-title":"Immunomodulatory effect of locoregional therapy in the tumor microenvironment","volume":"31","author":"Xie","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2026.124208_bib187","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124208_bib188","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26051936","article-title":"Advances in immunotherapy in hepatocellular carcinoma","volume":"26","author":"Bloom","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib189","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12929-022-00866-3","article-title":"Tumor microenvironment: barrier or opportunity towards effective cancer therapy","volume":"29","author":"Tiwari","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.biomaterials.2026.124208_bib190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7554\/eLife.95009","article-title":"Exploring the role of the immune microenvironment in hepatocellular carcinoma: implications for immunotherapy and drug resistance","volume":"13","author":"Fu","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.biomaterials.2026.124208_bib191","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2019.08.016","article-title":"Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma","volume":"69","author":"Elnaggar","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib192","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12951-022-01615-2","article-title":"Emerging nanobiotechnology for precise theranostics of hepatocellular carcinoma","volume":"20","author":"Xu","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biomaterials.2026.124208_bib193","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jconrel.2023.01.051","article-title":"The application of nanoparticles in immunotherapy for hepatocellular carcinoma","volume":"355","author":"Hu","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2026.124208_bib194","article-title":"A gas nanobomb to promote drug penetration and amplify TACE therapy for orthotopic liver tumor","author":"Chen","year":"2025","journal-title":"Adv. Mater."},{"issue":"49","key":"10.1016\/j.biomaterials.2026.124208_bib195","first-page":"10","article-title":"ZnS@BSA nanoclusters potentiate efficacy of cancer immunotherapy","volume":"33","author":"Cen","year":"2021","journal-title":"Adv. Mater."},{"issue":"33","key":"10.1016\/j.biomaterials.2026.124208_bib196","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/adma.202301352","article-title":"A sodium alginate-based multifunctional nanoplatform for synergistic chemo-immunotherapy of hepatocellular carcinoma","volume":"35","author":"Huang","year":"2023","journal-title":"Adv. Mater."},{"issue":"10","key":"10.1016\/j.biomaterials.2026.124208_bib197","doi-asserted-by":"crossref","first-page":"12679","DOI":"10.1021\/acsnano.0c01453","article-title":"A hepatocellular carcinoma targeting nanostrategy with hypoxia-ameliorating and photothermal abilities that, combined with immunotherapy, inhibits metastasis and recurrence","volume":"14","author":"Zhou","year":"2020","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124208_bib198","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12951-024-03030-1","article-title":"Targeted nanoparticle delivery unleashes synergistic photothermal and immunotherapeutic effects against hepatocellular carcinoma","volume":"22","author":"Babu","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"34","key":"10.1016\/j.biomaterials.2026.124208_bib199","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/advs.202400951","article-title":"Multifunctional biomimetic nanocarriers for dual-targeted immuno-gene therapy against hepatocellular carcinoma","volume":"11","author":"Sun","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biomaterials.2026.124208_bib200","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jconrel.2023.02.029","article-title":"Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy","volume":"356","author":"Xiao","year":"2023","journal-title":"J. Contr. Release"},{"issue":"17","key":"10.1016\/j.biomaterials.2026.124208_bib201","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/adhm.202200579","article-title":"Aggregation-induced emission (AIE) and magnetic resonance imaging characteristics for targeted and image-guided siRNA therapy of hepatocellular carcinoma","volume":"11","author":"Hou","year":"2022","journal-title":"Adv. Healthcare Mater."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124208_bib202","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1021\/nl061025k","article-title":"Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm","volume":"6","author":"Xia","year":"2006","journal-title":"Nano Lett."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124208_bib203","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/nl060860z","article-title":"The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications","volume":"6","author":"Vallhov","year":"2006","journal-title":"Nano Lett."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226002322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226002322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:25:06Z","timestamp":1793946306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961226002322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":202,"alternative-id":["S0142961226002322"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124208","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interventional therapy for hepatocellular carcinoma in the immunotherapy era: From mechanism exploration to materials innovation","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124208"}}